Skip to main content
. 2017 Sep 20;8(16):3356–3361. doi: 10.7150/jca.20784

Figure 3.

Figure 3

DMFS and OS rates in patients with stage I-II lung cancer. (A) DMFS was significantly reduced in the CTNB group as compared to the non-CTNB group (CTNB group, n = 113; non-CTNB group, n = 1121; P <0.001, log-rank test). (B) OS was significantly reduced in the CTNB group as compared to the non-CTNB group (CTNB group, n = 113; non-CTNB group, n = 1121; P = 0.002, log-rank test). (C) DMFS was significantly reduced in the CTNB group as compared to the non-CTNB group in the matched cohort (CTNB group, n = 113; non-CTNB group, n = 113; P = 0.032, log-rank test). (D) OS was similar for the two groups in the matched cohort (CTNB group, n = 113; non-CTNB group, n = 113; P = 0.086, log-rank test). DMFS: distant metastasis free survival. OS: overall survival.